New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
11:40 EDTTHLD, ZIOPThreshold higher after Ziopharm terminates STS drug development
Threshold Pharmaceuticals (THLD) shares are trading higher today after rival cancer drug discovery company Ziopharm (ZIOP) terminated its development of palifosfamide. WHAT'S NEW: Earlier today, Ziopharm announced that its Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma, or STS, in the first-line setting did not meet its primary endpoint of progression-free survival. Like Ziopharm, Threshold focuses on the discovery and development of cancer therapeutics and is also in the process of evaluating a drug to treat patients with soft tissue sarcoma with its development of TH-302. WHAT'S NOTABLE: Threshold's TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer. Both Phase 3 trials are being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TODAY'S PRICE ACTION: Shares of Threshold Pharmaceuticals are up 11c, or 2.3% to $4.90 in late morning trading. Meanwhile, shares of Ziopharm, which were downgraded by at least four analyst firms after its announcement, plunged 62% to $1.94.
News For THLD;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:38 EDTZIOPHigh option volume stocks: CTCT WYN DPM MXL CSOD PAGP HDP ZIOP QLYS ADS
Subscribe for More Information
07:10 EDTZIOPZIOPHARM says first patient enrolled in Phase 1 study of CAR T-Cell therapy
ZIOPHARM Oncology (ZIOP) announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells. The Sleeping Beauty transposon-transposase is a unique non-viral system for introducing genes encoding CARs and T-cell receptors into lymphocytes and is exclusively licensed by Intrexon Corporation (XON) through The University of Texas MD Anderson Cancer Center and accessed as part of ZIOPHARM's collaboration.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use